Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS): baseline characteristics of the EXPAND study population

被引：0
|
作者：
Kappos, L. [1 ,2 ,3 ,4 ]
Bar-Or, A. [5 ]
Cree, B. [6 ]
Fox, R. [7 ]
Giovannoni, G. [8 ]
Gold, R. [9 ]
Vermersch, P. [10 ]
Bhasin, P. [11 ]
Arnould, S. [12 ]
Sidorenko, T. [12 ]
Wallstroem, E. [12 ]
机构：
[1] Univ Basel Hosp, Neurol, Dept Med, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Neurol, Dept Clin Res, CH-4031 Basel, Switzerland
[3] Univ Basel Hosp, Neurol, Dept Biomed, CH-4031 Basel, Switzerland
[4] Univ Basel Hosp, Neurol, Dept Biomed Engn, CH-4031 Basel, Switzerland
[5] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada
[6] Univ Calif San Francisco, Multiple Sclerosis Ctr, San Francisco, CA 94143 USA
[7] Cleveland Clin, Neurol Inst, Mellen Ctr Treatment & Res Multiple Sclerosis, Cleveland, OH 44106 USA
[8] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England
[9] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany
[10] Univ Lille, Dept Neurol, Lille, France
[11] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[12] Novartis Pharma AG, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P649
引用
收藏
页码：317 / 318
页数：2
相关论文
共 50 条
  • [41] Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
    Ralf Gold
    Daniela Piani-Meier
    Ludwig Kappos
    Amit Bar-Or
    Patrick Vermersch
    Gavin Giovannoni
    Robert J. Fox
    Douglas L. Arnold
    Ralph H. B. Benedict
    Iris-Katharina Penner
    Nicolas Rouyrre
    Ajay Kilaru
    Göril Karlsson
    Shannon Ritter
    Frank Dahlke
    Thomas Hach
    Bruce A. C. Cree
    [J]. Journal of Neurology, 2022, 269 : 5093 - 5104
  • [42] Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
    Gajofatto, Alberto
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 3153 - 3157
  • [43] Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
    Regner-Nelke, Liesa
    Pawlitzki, Marc
    Willison, Alice
    Rolfes, Leoni
    Oezalp, Sinem-Hilal
    Nelke, Christopher
    Koelsche, Tristan
    Korsen, Melanie
    Grothe, Matthias
    Groppa, Sergiu
    Luessi, Felix
    Engel, Sinah
    Nelles, Gereon
    Bonmann, Eckhard
    Roick, Holger
    Friedrich, Anke
    Knorn, Philipp
    Landefeld, Harald
    Biro, Zoltan
    Ernst, Michael
    Bayas, Antonios
    Menacher, Martina
    Akgun, Katja
    Kleinschnitz, Christoph
    Ruck, Tobias
    Ziemssen, Tjalf
    Pul, Refik
    Meuth, Sven G.
    [J]. NEUROLOGICAL RESEARCH AND PRACTICE, 2022, 4 (01):
  • [44] The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis
    Samjoo, Imtiaz A.
    Worthington, Evelyn
    Haltner, Anja
    Cameron, Chris
    Nicholas, Richard
    Dahlke, Frank
    Adlard, Nicholas
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (07) : 1145 - 1156
  • [45] Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
    Mao-Draayers, Yang
    Wu, Qi
    Wang, Qin
    Dowling, Catherine
    Lundy, Steven
    Segal, Benjamin
    Wallstrom, Wallstrom
    [J]. NEUROLOGY, 2016, 86
  • [46] Baseline immunological profile in secondary progressive multiple sclerosis patients of Phase III EXPAND Trial
    Mao-Draayer, Yang
    Wu, Qi
    Wang, Qin
    Dowling, Catherine
    Lundy, Steve K.
    Segal, Benjamin Matthew M.
    Wallstroem, Erik
    Fox, David A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 13 - 13
  • [47] Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
    Mao-Draayer, Yang
    Wu, Qi
    Wang, Qin
    Lundy, Steve K.
    Dowling, Catherine
    Segal, Benjamin Matthew M.
    Fox, David
    Wallstroem, Erik
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 12 - 12
  • [48] The selective sphingosine 1-phosphate receptor modulator siponimod (BAF312): magnetic resonance imaging lesion and lymphocyte relationship in a phase 2 study in relapsing-remitting multiple sclerosis
    Hartung, H. -P.
    Pigeolet, E.
    Li, D.
    Hemmer, B.
    Kappos, L.
    Freedman, M. S.
    Stueve, O.
    Rieckmann, P.
    Montalban, X.
    Ziemssen, T.
    Zhang-Auberson, L.
    Wallstroem, E.
    Selmaj, K.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 426 - 427
  • [49] Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series
    Chang, Edward H.
    Hardy, Todd A.
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2024, 389
  • [50] Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study.
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Arnould, S.
    Sidorenko, T.
    Wolf, C.
    Wallstroem, E.
    Dahlke, F.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 828 - 829
12345